Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
NCT ID: NCT07000916
Last Updated: 2025-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2013-09-11
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).
Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.
These 5 cohorts will be subject to standardized clinical monitoring.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Occupational and Environmental Causes of Autoimmune Diseases
NCT07000903
This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE
NCT06698900
Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juvenile Idiopathic Arthritis and Autoinflammatory Diseases: Possible Biomarkers in the Differential Diagnosis of Other Febrile Diseases
NCT06718049
Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
NCT05443516
Scrutinizing the Heterogeneity of SLE: Defining Phenotypes
NCT03348774
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The first objective will be to include a progressive number of new young patients (≤ 50 years) in order to optimize and standardize care and clinical response objectives. The number of 25% of new incident cases will be sought with an increase of 20% each year during the 5 to 10 years of this project.
Population: JIA, RA/UA, SLE, dSS (American Congres of Rheumatology criteria). Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.
These 5 cohorts will be subject to standardized clinical monitoring and specific objectives that will make it possible to analyze the number of patients with a good control of the disease and/or a clinical remission, defined according to the international criteria.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
juvenile idiopathic arthritis (JIA)
aged \<= 16 y.o. recent diagnosis of JIA and DMARDs treatment-naive patients; aged \<18 y.o. recent diagnosis of JIA
No interventions assigned to this group
rheumatoid arthritis (RA)
aged =\>18; =\< 50 y.o. recent diagnosis of RA and DMARDs treatment-naive patients
No interventions assigned to this group
diffuse systemic sclerosis (dSS)
aged =\>18; =\< 50 y.o. recent diagnosis of dSS and DMARDs treatment-naive patients
No interventions assigned to this group
seronegative arthritis (UA)
aged =\>18; =\< 50 y.o. recent diagnosis of UA and DMARDs treatment-naive patients
No interventions assigned to this group
systemic lupus erythematosus (SLE)
aged =\>18; =\< 50 y.o. recent diagnosis of SLE and DMARDs treatment-naive patients
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.
Exclusion Criteria
* \> 50 years old
2 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université Catholique de Louvain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrick Durez, Pr
Role: STUDY_DIRECTOR
UCLouvain - IREC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLouvain
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cap 48 polyarthrite
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.